Merck acquires global rights to SciBrunch Therapeutics’ SPR2015, a preclinical oral KRAS G12D inhibitor, in a deal worth up ...
How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages Northwestern University economist ...
Celltrion a annoncé l’acquisition de 560 853 actions ordinaires pour un montant maximal de 100 milliards de wons entre le 30 septembre et le 29 décembre, afin de stabiliser le cours de ...
La société biopharmaceutique Celltrion prévoit de racheter 560 853 actions ordinaires pour un montant maximal de 100 milliards de wons entre le 30 septembre et le 29 décembre, afin ...
La empresa biofarmacéutica Celltrion planea recomprar 560.853 acciones ordinarias por un importe de hasta 100.000 millones ...
FDA Approves WELIREG Plus LENVIMA for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) ...
Celltrion ha ottenuto l'approvazione della Food and Drug Administration statunitense per avviare negli Stati Uniti uno studio ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and ...
The pembrolizumab combination matches Keytruda's indications in Japan and reduced administration time to about one to two minutes in company data.
Mercoledì, secondo un documento depositato presso la Borsa della Corea, Celltrion ha acquistato 544.299 azioni per un valore di circa 100 Mrd KRW. L'azienda biofarmaceutica ha reso noto che ...
Ivonescimab reduced the risk of death by 27% compared with Keytruda, also known as pembrolizumab, among previously untreated patients with advanced non-small cell lung cancer whose tumors expressed PD ...
A global investigation reveals how the high price of Merck’s blockbuster cancer drug Keytruda locks out patients in lower-income countries.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results